Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial

Gianfranco Ferraccioli, J. S. Smolen, P. Emery, W. Samborski, F. Berenbaum, O. R. Davies, W. Koetse, O. Purcaru, B. Bennett, H. Burkhardt

Risultato della ricerca: Contributo in rivistaArticolo in rivista

67 Citazioni (Scopus)

Abstract

This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
Lingua originaleEnglish
pagine (da-a)N/A-N/A
RivistaANNALS OF THE RHEUMATIC DISEASES
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Anti-TNF
  • DMARDs (biologic)
  • Disease Activity
  • Rheumatoid Arthritis

Fingerprint Entra nei temi di ricerca di 'Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial'. Insieme formano una fingerprint unica.

Cita questo